HER2+ MBC Case Discussion
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

Released: September 21, 2020

Expiration: September 20, 2021

Thomas Bachelot
Thomas Bachelot, MD, PhD
Adam M. Brufsky
Adam M. Brufsky, MD, PhD
Cristina Saura
Cristina Saura, MD, PhD

Activity

Progress
1
Course Completed

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:

  • Local therapy in the context of MBC
  • Choice of therapy after progression on available standards of care
  • Choice of trastuzumab deruxtecan and tucatinib based on patient presentation
  • Managing patients with CNS metastases
  • Managing interstitial lung disease

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/esmo-breast-sat